Ozsoy Saliha, Mavili Ertugrul, Aydin Murat, Turan Tayfun, Esel Ertugrul
Department of Psychiatry, Erciyes University Medical School, Turkey.
Hum Psychopharmacol. 2010 Mar;25(2):174-8. doi: 10.1002/hup.1093.
This study investigated thyroid volume, hormone levels and antibodies in long-term lithium-treated and lithium-naïve bipolar patients, some of whom underwent prospective follow-up evaluations.
Fourteen lithium-naïve patients, 13 long-term lithium-treated patients diagnosed with bipolar disorder and 12 healthy controls were included. Seven lithium-naïve patients were followed-up during their lithium receiving period (range 6-9 months). Thyroid volume and serum levels of thyroid hormones and antibodies were measured once in the long-term lithium-treated patients and controls, and twice in the lithium-naïve patients, i.e. before and after lithium treatment.
Mean thyroid volumes in the lithium-naïve patients were significantly higher than those in the controls. Long-term lithium-treated patients had significantly higher total thyroid volume than the lithium-naïve patients and the controls. Total thyroid volume in the patients after the lithium treatment was significantly higher than that before. Serum free thyroxine (fT4) levels in the long-term lithium-treated patients were lower than those in the lithium-naïve patients and the controls. In the lithium-naïve patients, after lithium treatment, free triiodothyronine (fT3) levels were lower, and thyroid stimulating hormone (TSH) levels were higher compared to those before lithium treatment.
The results suggest that thyroid enlargement and some alterations in thyroid hormones in bipolar patients may present even before lithium treatment and increase further with lithium treatment.
本研究调查了长期接受锂盐治疗和未接受锂盐治疗的双相情感障碍患者的甲状腺体积、激素水平及抗体情况,其中部分患者接受了前瞻性随访评估。
纳入14例未接受锂盐治疗的患者、13例诊断为双相情感障碍的长期接受锂盐治疗的患者以及12名健康对照者。7例未接受锂盐治疗的患者在接受锂盐治疗期间(6 - 9个月)接受随访。对长期接受锂盐治疗的患者和对照者测量一次甲状腺体积以及甲状腺激素和抗体的血清水平,对未接受锂盐治疗的患者测量两次,即在锂盐治疗前后各测量一次。
未接受锂盐治疗的患者的平均甲状腺体积显著高于对照组。长期接受锂盐治疗的患者的总甲状腺体积显著高于未接受锂盐治疗的患者和对照组。锂盐治疗后的患者的总甲状腺体积显著高于治疗前。长期接受锂盐治疗的患者的血清游离甲状腺素(fT4)水平低于未接受锂盐治疗的患者和对照组。在未接受锂盐治疗的患者中,锂盐治疗后,游离三碘甲状腺原氨酸(fT3)水平降低,促甲状腺激素(TSH)水平高于锂盐治疗前。
结果表明,双相情感障碍患者的甲状腺肿大及甲状腺激素的一些改变可能在锂盐治疗前就已出现,并随着锂盐治疗进一步加重。